WHO Pharmaceuticals letter No. 4, 2010
http://www.who.int/medicines/publications/newsletter/2010news_4_9Aug.pdf
Content
Regulatory Matters
Dextropropoxyphene ..........................1
Gemtuzumab ozogamicin..................1
Leflunomide ...............................1
Long-Acting Beta-Agonists..................2
Omeprazole..........................3
Orlistat............................3
Proton pump inhibitors ..................................3
Quinine.........................................................4
Seasonal trivalent influenza vaccination.................5
Sodium valproate and carbapenems...................6
Tramadol............................................6
Varenicline tartrate ...............................6
Safety of Medicines
Acitretin ...............................................8
Angiotensin Receptor Blockers...........................8
H1N1 pandemic vaccines and antiviral..................8
Intravenous paracetamol.........................9
Methylphenidate......................................9
Olmesartan..............................................9
Pregabalin ............................................10
Rivastigmine transdermal patch...................10
Zoledronic acid.........................................10
Fraudulent Tamiflu .....................................11
Features
Workshop on Pharmaceutical Development of Paediatric
Formulations...................................12
HSA hosts the First Pharmacovigilance Training for ASEAN
Countries..........................................................15
Seventh Meeting of the WHO Advisory .....17